Karuna Therapeutics, Inc., A Bristol Myers Squibb Company

This study tested the safety of a new drug called KarXT in 173 adults with schizophrenia. Researchers slowly increased the dose to see how well participants tolerated it and whether food affected the drug. The main goal was to track side effects, with secondary measures looking a…

This phase 3 trial tested KarXT, a combination of two drugs, as an add-on treatment for 396 adults with schizophrenia whose symptoms were not well controlled by their current medication. Over 6 weeks, researchers measured changes in symptom severity using a standard rating scale.…

This study tested a new drug called KarXT in 202 Chinese adults hospitalized for schizophrenia. The goal was to see if KarXT could reduce symptoms like hallucinations and delusions better than a placebo over 5 weeks, followed by a 12-week period where everyone received the drug. …

This Phase 3 study tested the long-term safety and effectiveness of KarXT, a combination of two drugs (xanomeline and trospium), in 566 adults with schizophrenia. Participants took KarXT twice daily for up to 52 weeks. The main goal was to see how safe and tolerable the drug is o…

This completed study looked at how much of the drug KarXT (xanomeline/trospium chloride) gets into the breast milk and blood of 10 healthy women who were breastfeeding. The goal was to measure drug levels and estimate how much an infant might be exposed to. The results will help …

This study looked at how a new drug called KarXT interacts with three common mood stabilizers (lithium, valproic acid, and lamotrigine) in 133 healthy adults. Researchers measured drug levels in the blood and checked for side effects. The goal was to understand if these drugs aff…